公开(公告)号：US20190350959A1

公开(公告)日：2019-11-21

申请号：US16396017

申请日：2019-04-26

Applicant: Epizyme, Inc.

Inventor： Edward James OLHAVA ,  Angelos DOVLETOGLOU ,  Bruce REHLAENDER

IPC: A61K31/7076 ,  A61K47/40 ,  A61K9/08 ,  A61K9/00

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

公开(公告)号：US20210353661A1

公开(公告)日：2021-11-18

申请号：US17215491

申请日：2021-03-29

Applicant: Epizyme, Inc.

Inventor： Edward James OLHAVA ,  Angelos DOVLETOGLOU ,  Bruce REHLAENDER

IPC: A61K31/7076 ,  A61K9/00 ,  A61K47/40 ,  A61K9/08

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

公开(公告)号：US20210251887A1

公开(公告)日：2021-08-19

申请号：US17130936

申请日：2020-12-22

Applicant: Epizyme, Inc.

Inventor： Edward James OLHAVA ,  Angelos DOVLETOGLOU ,  Steve WALD ,  Bruce REHLAENDER

IPC: A61K9/00 ,  A61K31/7076 ,  A61P35/02 ,  A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

公开(公告)号：US20190388335A1

公开(公告)日：2019-12-26

申请号：US16433259

申请日：2019-06-06

Applicant: Epizyme, Inc.

Inventor： Edward James OLHAVA ,  Angelos DOVLETOGLOU ,  Steve WALD ,  Bruce REHLAENDER

IPC: A61K9/00 ,  A61K47/40 ,  A61K47/26 ,  A61K47/12 ,  A61K47/02 ,  A61K31/7076

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

公开(公告)号：US20160022725A1

公开(公告)日：2016-01-28

申请号：US14777284

申请日：2014-03-14

Applicant: EPIZYME, INC.

Inventor： Edward James Olhava ,  Angelos DOVLETOGLOU ,  Bruce REHLANENDER

IPC: A61K31/7076 ,  A61K9/00

CPC classification number: A61K31/7076 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/40 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

Abstract translation: 本发明提供（2R，3R，4S，5R）-2-（6-氨基-9H-嘌呤-9-基）-5 - （（（（1r，3S）-3-（2-（ （叔丁基）-1H-苯并[d]咪唑-2-基）乙基）环丁基）（异丙基）氨基）甲基）四氢呋喃-3,4-二醇及其水合物及其治疗疾病的方法，其中DOT1- 介导的蛋白质甲基化发挥作用，如癌症和神经系统疾病。